ProMIS Neurosciences (PMN) AI Stock Analysis

• Market Cap: $19.90M
• Dividend Yield: N/A
• Average Volume (3M): 30.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: N/A
• EPS Growth: 98.61%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 32,689,190
• 10 Day Avg. Volume: 35,291
• 30 Day Avg. Volume: 30,227
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 916.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.

Positive Factors

Dosing Efficiency

The half-life of PMN310 was determined to be approximately 25 days, which supports once-per-month dosing, enhancing patient convenience and compliance.

Financial Position

The recently completed PIPE financing provides an initial upfront funding of $30.3M with the potential for an additional $92.4M, boosting the company's financial resources.

Safety and Tolerability

PMN310 demonstrated a favorable safety and tolerability profile with no treatment-emergent serious adverse events observed.

Negative Factors

Cash Reserves

The company finished with only $1.0M in cash and cash equivalents, a concern for ongoing operational expenses.

Complexity in Targeting TDP-43

Targeting TDP-43 involves complex dosing determinations due to its essential role in cells and its involvement in multiple conditions, posing potential challenges in treatment development.

ProMIS Neurosciences Business Overview & Revenue Model

Company Description

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

How the Company Makes Money

ProMIS Neurosciences generates revenue through a combination of research and development collaborations, licensing agreements, and potential future sales of its proprietary therapeutics. The company may receive upfront payments, milestone payments, and royalties from its partnerships and licensing deals. Additionally, as its products advance through clinical development and potentially receive regulatory approval, ProMIS may earn revenue from product sales. The company's revenue model is highly dependent on successful clinical trials, strategic alliances, and partnerships with larger pharmaceutical companies to commercialize its therapies.

ProMIS Neurosciences Financial Statement Overview

Summary

ProMIS Neurosciences demonstrates significant financial challenges, with no revenue generation and consistent net losses. The balance sheet is stable with no debt, but lacks significant equity for growth. Cash flows highlight dependence on external financing, indicating potential liquidity risks if funding sources diminish.

Income Statement

The company has reported zero revenue over the periods, indicating no sales. The net income is negative, reflecting ongoing losses. The EBITDA margin is positive in TTM (Trailing-Twelve-Months), suggesting some improvement in operational expenses, but EBIT remains negative, showcasing profitability challenges.

Balance Sheet

The balance sheet shows no debt, which is a positive indicator of leverage stability. However, the equity is limited, restricting growth potential. The equity ratio is reasonable at 29.7% in TTM, suggesting a modest level of financial stability but limited resources for expansion.

Cash Flow

Operating cash flow is negative, indicating cash outflows from core operations. Free cash flow is also negative, suggesting that the company is not generating cash for reinvestment or dividends. The financing cash flows are substantial, indicating reliance on external funding for operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	―	―	―
	Gross Profit
0.00	-10.44M	-21.78M	―	―	―
	EBIT
-14.70M	-18.90M	-23.38M	―	―	―
	EBITDA
2.98M	-17.81M	-29.88M	-9.33M	―	―
	Net Income Common Stockholders
-563.35K	-17.51M	-12.74M	―	―	―
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.32M	16.75M	8.01M	21.48M	1.11M	1.70M
	Total Assets
5.31M	18.04M	9.38M	22.44M	1.38M	2.07M
	Total Debt
0.00	0.00	0.00	4.94M	0.00	0.00
	Net Debt
―	-16.69M	-7.96M	-16.49M	-1.03M	-1.66M
	Total Liabilities
634.39K	13.07M	8.68M	15.28M	2.40M	1.68M
	Stockholders Equity
4.67M	4.97M	―	7.16M	-1.02M	398.12K
Cash Flow		Free Cash Flow
-22.01M	-14.37M	-17.04M	―	―	―
	Operating Cash Flow
-22.01M	-14.37M	-17.03M	―	―	―
	Investing Cash Flow
0.00	―	-1.98K	94.33K	―	―
	Financing Cash Flow
26.66M	23.52M	6.49M	25.20M	3.01M	4.10M

ProMIS Neurosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.72, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 45.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMN.

ProMIS Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
BOLT	44 Neutral	$13.84M	―	-74.28%	―	-2.36%	9.68%
PMN	38 Underperform	$19.90M	―	27.46%	―	―	98.61%
NERV	37 Underperform	$11.96M	9.36	>-0.01%	―	―	―
CGTX	32 Underperform	$23.37M	―	-157.19%	―	―	-0.38%
NRSN	28 Underperform	$25.43M	―	-2880.11%	―	―	24.35%

ProMIS Neurosciences Corporate Events

ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial

On February 25, 2025, ProMIS Neurosciences announced the dosing of multiple patients in its Phase 1b PRECISE-AD clinical trial for PMN310, a drug candidate for Alzheimer’s disease. This milestone highlights the company’s commitment to addressing the urgent need for targeted AD therapies by selectively targeting toxic oligomers, a key driver of disease progression. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim results expected in the first half of 2026 and topline results in the second half of 2026. The trial’s design is expected to provide robust clinical data that could differentiate PMN310 from other AD treatments, potentially offering a more effective and well-tolerated option for patients.

ProMIS Neurosciences Announces COO Position Termination

On February 14, 2025, ProMIS Neurosciences Inc. announced the separation of Gavin T. Malenfant from his role as Chief Operating Officer, coinciding with the termination of the COO position without plans for a replacement. This move reflects a strategic shift that could impact the company’s operational structure and potential cost-saving measures, influencing both internal efficiencies and external perceptions.

ProMIS Neurosciences Highlights Neurodegenerative Disease Focus

On January 27, 2025, ProMIS Neurosciences Inc. announced an updated corporate presentation highlighting its focus on addressing unmet needs in neurodegenerative diseases. The company has a diverse pipeline, including the lead program PMN310 for Alzheimer’s, which is undergoing a Phase 1b clinical trial. The company emphasizes its potential to develop safer, more effective therapies by targeting specific misfolded proteins, supported by a seasoned leadership team and significant funding secured in July 2024.